The core of Amazon Bio Discovery lies in its ability to route AI-designed antibody candidates directly to leading DNA Synthesis…
Read More
OrsoBio’s LXR Inverse Agonist Shows Promise for Hard-to-Treat Triglyceride Disorders, Paving New Path Beyond GLP-1 Dominance
OrsoBio, a specialized biotechnology firm dedicated to pioneering therapies for obesity and its associated metabolic conditions, is strategically charting a…
Read More
Sai Life Sciences Plans to Recruit 700+ Professionals in FY27 as Indian CRDMO Demand Accelerates
Hyderabad, India – Sai Life Sciences, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced an ambitious…
Read More
Insilico CEO Sees Potentially $2.75 Billion Collaboration as ‘Fusing Lilly’s Clinical Excellence’ with Insilico’s ‘End-to-End AI Engine’
On March 29, Insilico Medicine, a pioneer in artificial intelligence-driven drug discovery, announced a landmark collaboration with pharmaceutical giant Eli…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
A Deep Dive into the Trial Results CagriSema, a novel combination therapy comprising cagrilintide and semaglutide, delivered an average weight…
Read More
Closing the Information Gap: ETH Zürich Team Integrates Function and Binding in One Drug Screening Assay
In a significant advancement poised to reshape the landscape of pharmaceutical development, a collaborative team from ETH Zürich and the…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk has announced significant positive results from a Phase 2 trial of its experimental triple agonist, UBT251, reporting a…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry grapples with an intractable problem: the escalating cost and protracted timelines of drug development, coupled with persistently…
Read More
From List Price to Net Price: How Finance Leaders Decode Real Drug Costs
In the intricate landscape of the healthcare industry, public discourse surrounding drug pricing frequently begins and ends with the list…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly’s investigational drug, retatrutide, a pioneering first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has delivered extraordinary results…
Read MoreYOU MAY HAVE MISSED
